The Next Big Thing In Biotech: 2013 Outlook
Dec 21, 2012 | 5:30 AM EST - 

Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.

Columnist Conversations

I am all in short SPY now.
Diamonds (DIA) may be a girl's best friend, but it's time to sell them. The SPDR Dow Jones Industrial Average ...
Continues to be TLT. Slipping a bit now from its highs. Indices might follow a bit lower now.
Remove GM long. Add SPY and QQQ shorts. (Just reshorted QQQ at $105.50)


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.